Comparative effectiveness of Glargine 300 U/mL vs. Degludec 100 U/mL in patients with type 2 diabetes switching from 1? generation basal insulins

被引:6
作者
Buzzetti, Raffaella [1 ]
Fadini, Gian Paolo [2 ]
Nicolucci, Antonio [3 ]
Larosa, Monica [4 ]
Rossi, Maria Chiara [3 ]
Cucinotta, Domenico [5 ]
机构
[1] Sapienza Univ Rome, Dept Expt Med, Rome, Italy
[2] Univ Padua, Dept Med, Padua, Italy
[3] CORESEARCH Ctr Outcomes Res & Clin Epidemiol, Pescara, Italy
[4] Sanofi Milan, Med Affairs, Milan, Italy
[5] Univ Messina, Dept Clin & Expt Med, Messina, Italy
关键词
Type; 2; diabetes; Basal insulin; Switch; Glargine; 300; Degludec; 100; Effectiveness; Safety;
D O I
10.1016/j.numecd.2022.06.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aims: Data on second generation basal insulin (2BI) in people with type 2 diabetes (T2D) generated by clinical trials still need confirmation in real-world clinical set-tings. This study aimed at assessing the comparative effectiveness of 2BI [Glargine 300 U/mL (Gla-30 0) vs. Degludec 100 U/mL (Deg-10 0)] in T2D Italian patients switching from first gener-ation basal insulins (1BI).Methods and results: This was a retrospective, non-inferiority, multicenter study. Patients switch-ing to Gla-30 0 or Deg-10 0 from 1BI were 1:1 propensity score matched (PSM). Changes during 6 months in continuous endpoints were assessed through linear mixed models. Incidence rates (IR) of hypoglycemia (episodes per patient-months) were compared using Poisson regression.Each PSM cohort included 593 patients. HbA1c decreased from baseline (8.7%) to 6 months by-0.58% (95%CI-0.69;-0.47) in Gla-30 0 group and-0.50% (95%CI-0.61;-0.39) in Deg-10 0 group, confirming the non-inferiority of Gla-30 0 vs. Deg-100. No between-group differences emerged: FBG was reduced by about 20 mg/dl with both 2BI, mean dose of 2BI (24.5 U, 0.3 U/Kg at the first prescription) was suboptimally titrated during 6 months (+1.34 U in Gla-30 0 and + 1.76 U in Deg-10 0), body weight showed minor changes.IR of hypoglycemia <54 mg/dl was 0.32 (95%CI 0.21; 0.49) in Gla-30 0 group and 0.19 (95%CI 0.11; 0.33) in Deg-10 0 group (p Z 0.14). Conclusion: In subjects with T2D, switching to 2BI from 1BI was associated with similar improve-ments in glycemic control, low hypoglycemia rates and no weight gain in real-life setting. Clinical inertia, represented by late treatment intensification and suboptimal titration, represents a major issue in Italy. 2022 The Author(s). Published by Elsevier B.V. on behalf of The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:2255 / 2263
页数:9
相关论文
共 18 条
[1]   6. Glycemic Targets: Standards of Medical Care in Diabetes-2021 [J].
不详 .
DIABETES CARE, 2021, 44 :S73-S84
[2]   Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples [J].
Austin, Peter C. .
STATISTICS IN MEDICINE, 2009, 28 (25) :3083-3107
[3]   Switching to insulin glargine 300 units/mL in real-world older patients with type 2 diabetes (DELIVER 3) [J].
Bailey, Timothy S. ;
Wu, Jasmanda ;
Zhou, Fang L. ;
Gupta, Rishab A. ;
Menon, Arjun A. ;
Berhanu, Paulos ;
Westerbacka, Jukka ;
Van Vleet, John ;
Blonde, Lawrence .
DIABETES OBESITY & METABOLISM, 2019, 21 (11) :2384-2393
[4]   New Insulin Glargine 300 Units.mL-1 Provides a More Even Activity Profile and Prolonged Glycemic Control at Steady State Compared With Insulin Glargine 100 Units.mL-1 [J].
Becker, Reinhard H. A. ;
Dahmen, Raphael ;
Bergmann, Karin ;
Lehmann, Anne ;
Jax, Thomas ;
Heise, Tim .
DIABETES CARE, 2015, 38 (04) :637-643
[5]   Insulin glargine 300 units/mL for the treatment of individuals with type 2 diabetes in the real world: A review of the DELIVER programme [J].
Blonde, Lawrence ;
Bailey, Timothy ;
Sullivan, Sean D. ;
Freemantle, Nick .
DIABETES OBESITY & METABOLISM, 2021, 23 (08) :1713-1721
[6]   How conclusive is the CONCLUDE trial? [J].
Del Prato, Stefano .
DIABETOLOGIA, 2020, 63 (04) :692-697
[7]   Real-world outcomes of treatment with insulin glargine 300 U/mL versus standard-of-care in people with uncontrolled type 2 diabetes mellitus [J].
Freemantle, Nick ;
Mauricio, Didac ;
Giaccari, Andrea ;
Bailey, Timothy ;
Roussel, Ronan ;
Franco, Denise ;
Berthou, Baptiste ;
Pilorget, Valerie ;
Westerbacka, Jukka ;
Bosnyak, Zsolt ;
Bonnemaire, Mireille ;
Cali, Anna M. G. ;
Nguyen-Pascal, My-Lien ;
Penfornis, Alfred ;
Perez-Maraver, Manuel ;
Seufert, Jochen ;
Sullivan, Sean D. ;
Wilding, John ;
Wysham, Carol ;
Davies, Melanie .
CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (04) :571-581
[8]   Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice [J].
Goldman, Jennifer ;
Kapitza, Christoph ;
Pettus, Jeremy ;
Heise, Tim .
CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (10) :1821-1831
[9]   Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes [J].
Heise, T. ;
Nosek, L. ;
Bottcher, S. G. ;
Hastrup, H. ;
Haahr, H. .
DIABETES OBESITY & METABOLISM, 2012, 14 (10) :944-950
[10]   Comparative Effectiveness of Switching From First-Generation Basal Insulin to Glargine 300 U/ml or Degludec 100 U/ml in Type 1 Diabetes: The RESTORE-1 Study [J].
Laviola, Luigi ;
Porcellati, Francesca ;
Bruttomesso, Daniela ;
Larosa, Monica ;
Rossi, Maria Chiara ;
Nicolucci, Antonio .
DIABETES THERAPY, 2021, 12 (02) :509-525